N-(4-fluorobenzyl)-3-hydroxy-7,8,8-trimethyl-4-oxo-4,6,7,8-tetrahydroimidazo[1,5-a]pyrimidine-2-carboxamide | 857664-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(4-fluorobenzyl)-3-hydroxy-7,8,8-trimethyl-4-oxo-4,6,7,8-tetrahydroimidazo[1,5-a]pyrimidine-2-carboxamide
• 英文别名: N-[(4-fluorophenyl)methyl]-3-hydroxy-7,8,8-trimethyl-4-oxo-6H-imidazo[1,5-a]pyrimidine-2-carboxamide
• CAS: 857664-58-5
• 化学式: C₁₇H₁₉FN₄O₃
• 分子量: 346.361
• InChiKey: ZMNBZCGHGFFNNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  85.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 2-(1-amino-1-methylethyl)-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine-4-carboxamide hydrochloride 在 sodium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 N-(4-fluorobenzyl)-3-hydroxy-7,8,8-trimethyl-4-oxo-4,6,7,8-tetrahydroimidazo[1,5-a]pyrimidine-2-carboxamide
  参考文献：
  名称：

  N-（4-氟苄基）-3-羟基-9,9-二甲基-4-氧代-6,7,8,9-四氢-4 H-吡嗪并[1,2 - a ]嘧啶-2-羧酰胺类有效的HIV-1整合酶抑制剂

  摘要：

  一类新型的四氢吡喃并嘧啶-2-羧酰胺已被鉴定为HIV-1整合酶抑制剂。初始铅的优化最终发现了一系列对酶具有高效力的化合物，其抗病毒细胞活性与Raltegravir（第一种HIV-1整合酶抑制剂）所显示的活性相当。

  DOI：

  10.1016/j.bmcl.2009.05.098

文献信息

• HIV Integrase Inhibitors
  申请人：Summa Vincenzo

  公开号：US20090253681A1

  公开（公告）日：2009-10-08

  Compounds of Formula I are inhibitors of FHV integrase and inhibitors of FHV replication (I), wherein m, n, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 ; R 8 , R 9 and R 10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HTV infection and ADDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  式I的化合物是FHV整合酶的抑制剂和FHV复制的抑制剂（I），其中m，n，X，R1，R2，R3，R4，R5，R6，R7；R8，R9和R10在此被定义。这些化合物可用于预防或治疗HTV感染以及预防、治疗或延缓艾滋病的发病。这些化合物可作为化合物本身或药学上可接受的盐的形式用于对抗HTV感染和ADDS。这些化合物及其盐可作为药物组成部分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
• HIV INTEGRASE INHIBITORS
  申请人：Summa Vincenzo

  公开号：US20110257162A1

  公开（公告）日：2011-10-20

  Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein m, n, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  公式I的化合物是HIV整合酶抑制剂和HIV复制抑制剂，其中m，n，X，R1，R2，R3，R4，R5，R6，R7，R8，R9和R10在此定义。这些化合物对于预防或治疗HIV感染以及预防，治疗或延迟艾滋病的发作非常有用。这些化合物可以作为化合物本身或以药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可以作为药物组成部分，可选地与其他抗病毒药物，免疫调节剂，抗生素或疫苗组合使用。
• Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase
  申请人：Mikamiyama Hidenori

  公开号：US20070149556A1

  公开（公告）日：2007-06-28

  Compounds of Formula (1), pharmaceuticals containing the same, especially anti-HIV agents having anti viral activity, especially inhibitory activity against HIV integrase, wherein X represents either one of the following groups: (wherein, C ring is nitrogen-containing aromatic heterocyclic ring in which at least one atom in atoms neighboring the atom bound to the pyrimidine ring is unsubstituted nitrogen atom; R 10 is hydrogen or lower alkyl; D ring is aryl or heteroaryl) Z 1 and Z 3 each is independently a single bond, O, S, S (═O) or SO 2 ; Z 2 is a single bond, lower alkylene or lower alkenylene; Ar is optionally substituted aryl or optionally substituted heteroaryl; R 1 is lower alkyl, substituted lower alkyl or the like; R 2 is a hydrogen atom or optionally substituted lower alkyl; or R 1 and R 2 may form, together with an adjacent atom, an optionally substituted heterocyclic ring, a pharmaceutically acceptable salt or a solvate thereof.
• Hydroxypyrimidinone derivatives having inhibitory activity against HIV integrase
  申请人：Mikamiyama Hidenori

  公开号：US20100204237A1

  公开（公告）日：2010-08-12

  Compounds of Formula (1), pharmaceuticals containing the same, especially anti-HIV agents having anti viral activity, especially inhibitory activity against HIV integrase, wherein X represents either one of the following groups: (wherein, C ring is nitrogen-containing aromatic heterocyclic ring in which at least one atom in atoms neighboring the atom bound to the pyrimidine ring is unsubstituted nitrogen atom; R 10 is hydrogen or lower alkyl; D ring is aryl or heteroaryl) Z 1 and Z 3 each is independently a single bond, O, S, S(═O) or SO 2 ; Z 2 is a single bond, lower alkylene or lower alkenylene; Ar is optionally substituted aryl or optionally substituted heteroaryl; R 1 is lower alkyl, substituted lower alkyl or the like; R 2 is a hydrogen atom or optionally substituted lower alkyl; or R 1 and R 2 may form, together with an adjacent atom, an optionally substituted heterocyclic ring, a pharmaceutically acceptable salt or a solvate thereof.
• US7745453B2
  申请人：——

  公开号：US7745453B2

  公开（公告）日：2010-06-29